G
The National Center for Advancing Translational Sciences (NCATS) has used recombinant human proteins from R&D Systems for the majority of cells used in assays since its inception. Any recombinant human proteins used in this context must meet specific measurements of purity and consistency from batch to batch to provide consistent cell growth and viability. In addition, numerous batches of cells have been grown using recombinant human proteins from R&D Systems in NCATS CRM and the results was consistent and predictable growth resulting in successful assays.
In compliance with Federal Acquisition Regulation (FAR) 13.106-1(b) Soliciting from a single source. This notice of intent is not a request for competitive proposals, however; all responses received, before the closing date, of this announcement will be considered by the Government. A determination by the Government not to compete this proposed acquisition is based upon responses to this notice and is solely within the discretion of the Government. It is anticipated that the RFQ NIH-NICHD-17-299 will be available five (5) days after the publication date of this synopsis. Receipt of quotations will be due three (3) days after the release of the RFQ. All interested parties to this solicitation may request a copy of the RFQ package in writing to the attention of Ms. Patricia Haun at Eunice Kennedy Shriver National Institute Child Health and Human Development (NICHD), 6710B Rockledge Drive, Room 1159C, Bethesda, MD 20892 or via email [email protected]. All requests must contain offerors name, address, telephone number and fax number. Email addresses are encouraged but not mandatory